Endophthalmitis
diseaseOn this page
Summary
Endophthalmitis (MONDO:0016047) is a disease (an umbrella term covering 8 Mondo subtypes) and 41 clinical trials. Top therapeutic interventions include moxifloxacin, cefuroxime, and clindamycin. A subtype of inflammatory disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 8 Mondo subtypes
- Clinical trials: 41
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | endophthalmitis |
| Mondo ID | MONDO:0016047 |
| MeSH | D009877 |
| Orphanet | 199323 |
| DOID | DOID:4692 |
| ICD-11 | 1211141166 |
| NCIT | C34586 |
| SNOMED CT | 1847009 |
| UMLS | C0014236 |
| MedGen | 8633 |
| GARD | 0020333 |
| MedDRA | 10014801 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of inflammatory disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › inflammatory disease › endophthalmitis
Related subtypes (93): chorioamnionitis, pyometritis, uvulitis, mastoiditis, pelvic inflammatory disease, tonsillitis, nasopharyngitis, petrositis, nephritis, esophagitis, geniculate ganglionitis, epicondylitis, labyrinthitis, lymphadenitis, cheilitis, neuritis, vaginitis, hepatitis, pharyngitis, hidradenitis, gastroenteritis, dermatitis, bursitis, laryngitis, keratitis, endocervicitis, conjunctivitis, spondylitis, thyroiditis, diverticulitis, neuronitis, mediastinitis, epididymitis, blepharitis, cholangitis, dacryoadenitis, fasciitis, chronic inflammation of lacrimal passage, dacryocystitis, periostitis, gastritis, pancreatitis, periodontitis, encephalomyelitis, placental villitis, prostatitis, urethritis, otitis media, perianal Crohn disease, proctitis, arthritic joint disease, oral tuberculosis, parotitis, pericarditis, sinusitis, cystitis, panniculitis, balanitis, chronic inflammatory demyelinating polyradiculoneuropathy, glossitis, mastitis, oophoritis, orchitis, perinephritis, pulpitis, rheumatic heart disease, vulvitis, thromboangiitis obliterans, STING-associated vasculopathy with onset in infancy, chronic granulomatous disease, IgG4-related pachymeningitis, vasculitis, chronic pneumonitis of infancy, uveitis, mucositis, amnionitis, diaphragmitis, gonococcal cervicitis, posthitis, myositis disease, omphalitis, ear infection, radiculitis, tracheobronchitis, ureteritis, enthesitis, inflammation of heart layer, serositis, pneumonitis, immune reconstitution inflammatory syndrome, multiple evanescent white dot syndrome, isolated anogenital granulomatosis, myelin oligodendrocyte glycoprotein antibody-associated disease
Subtypes (8): cytomegalovirus retinitis, histoplasmosis retinitis, gonococcal endophthalmia, purulent endophthalmitis, infectious posterior uveitis, infectious anterior uveitis, corneal infection, parasitic endophthalmitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Moxifloxacin | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ciprofloxacin.
Clinical trials & evidence
Clinical trials
Clinical trials: 41.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 24 |
| PHASE4 | 7 |
| PHASE3 | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00398658 | PHASE4 | COMPLETED | Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis |
| NCT00461656 | PHASE4 | COMPLETED | Povidone-iodine Antisepsis for Strabismus Surgery |
| NCT02324166 | PHASE4 | UNKNOWN | Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain |
| NCT03363295 | PHASE4 | COMPLETED | Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis |
| NCT03634852 | PHASE4 | COMPLETED | A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery |
| NCT04403334 | PHASE4 | COMPLETED | Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin |
| NCT05079854 | PHASE4 | UNKNOWN | Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis |
| NCT03244072 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery |
| NCT00000130 | PHASE3 | COMPLETED | Endophthalmitis Vitrectomy Study (EVS) |
| NCT02590523 | PHASE3 | SUSPENDED | Intracameral Antibiotic Safety Study |
| NCT02770729 | PHASE3 | TERMINATED | Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis. |
| NCT04568213 | PHASE3 | COMPLETED | Hypochlorous Acid Disinfection Prior to Cataract Surgery |
| NCT02595359 | PHASE2 | COMPLETED | Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis |
| NCT04212078 | PHASE1/PHASE2 | UNKNOWN | Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime |
| NCT04212429 | PHASE1/PHASE2 | UNKNOWN | The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% |
| NCT04214821 | PHASE1/PHASE2 | UNKNOWN | The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% |
| NCT05162625 | PHASE2 | UNKNOWN | Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial |
| NCT05372861 | Not specified | RECRUITING | Nanopore Sequencing in Ophthalmology |
| NCT05432336 | Not specified | RECRUITING | Complex Ocular Infection, Optimization of Microbiological Diagnosis |
| NCT06673784 | Not specified | NOT_YET_RECRUITING | Evaluation and Risk Factors of Post-traumatic Endophthalmitis |
| NCT07175311 | Not specified | RECRUITING | Vascular Changes Associated With Endophthalmitis. |
| NCT07176130 | Not specified | ACTIVE_NOT_RECRUITING | Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore |
| NCT00136344 | Not specified | COMPLETED | Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery |
| NCT00335231 | Not specified | WITHDRAWN | Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery |
| NCT00406913 | Not specified | COMPLETED | Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery |
| NCT00730938 | Not specified | COMPLETED | The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery |
| NCT01323868 | Not specified | COMPLETED | Endogenous Endophthalmitis in the Inpatient Setting |
| NCT01496794 | Not specified | TERMINATED | Endophthalmitis Cultures |
| NCT02309736 | Not specified | WITHDRAWN | OTX-14-002: Device Exposure Registry |
| NCT02810587 | Not specified | UNKNOWN | Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics |
| NCT02818062 | Not specified | COMPLETED | Severe Intraocular Infection |
| NCT03420820 | Not specified | UNKNOWN | Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection |
| NCT03812640 | Not specified | UNKNOWN | Nylon Verus Polyglactin Corneal Suture in Pediatric Cataract Surgery |
| NCT03968341 | Not specified | UNKNOWN | Study of Intraocular Concentrations (Aqueous Humor, Vitreous Humor) of Antibiotics After Local and/or Systemic Administration in Endophthalmitis |
| NCT04035369 | Not specified | UNKNOWN | Endophthalmitis Post Intravitreal Injections |
| NCT04075669 | Not specified | UNKNOWN | Multiplex Strip Polymerase Chain Reaction for Diagnosis of Eye Infection Diseases From Corneal Scraping Samples |
| NCT04192994 | Not specified | COMPLETED | Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis |
| NCT05249413 | Not specified | COMPLETED | Early Vitrectomy for Endophthalmitis After Cataract Surgery |
| NCT06268561 | Not specified | UNKNOWN | Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months |
| NCT06755177 | Not specified | COMPLETED | Clinical Features and Visual Prognosis of Infectious Endophthalmitis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MOXIFLOXACIN | 4 | 7 |
| CEFUROXIME | 4 | 6 |
| CLINDAMYCIN | 4 | 3 |
| LEVOFLOXACIN ANHYDROUS | 4 | 2 |
| CEFAZOLIN | 4 | 1 |
| GENTAMICIN | 4 | 1 |
| MUPIROCIN | 4 | 1 |
| OFLOXACIN | 4 | 1 |
| POLYGLACTIN 910 | 3 | 1 |
| CHEMBL5421678 | 0 | 1 |
| CHEMBL4793658 | 0 | 1 |
| GENTAMICIN C1 | 0 | 1 |